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Abstract
Background Endometrial carcinoma is the most distressing
cause of abnormal vaginal bleeding. The intention of clinical
management in the case of postmenopausal bleeding is to
achieve an accurate diagnosis without overinvestigation.
Method We studied the available literature on the diag-
nostic evaluation of postmenopausal women with vaginal
bleeding, accentuating the most important aspects on this
topic: the accuracy of sonography and endometrial biopsy
in predicting endometrial hyperplasia and endometrial car-
cinoma.
Results The accuracy of the above tests in predicting endo-
metrial hyperplasia and endometrial carcinoma is a subject
of continuing debate. reover, in the last decades, there
has been an explosion of publications indicating that ultra-
sound may be useful in predicting endometrial pathology.
Conclusion Since advanced endometrial carcinoma has
been known to occur in cases without noticeable endome-
trial thickness on ultrasound, the clinician should beware of
the diagnostic evaluation of postmenopausal women with
vaginal bleeding.
Keywords Postmenopausal bleeding · Endometrial 
thickness · Biopsy
Introduction
Endometrial cancer is predominantly a disease of postmeno-
pausal women, most cases occurring in the sixth and seventh
decades, with less than 5% of cases in women under 40 years
of age. The lifetime risk of developing endometrial cancer is
1.1% while the lifetime risk of dying of endometrial cancer is
0.4%, reXecting the good prognosis of the condition with
early diagnosis [1]. Vaginal bleeding is the presenting sign in
more than 90% of postmenopausal patients with endometrial
carcinoma. However, depending on age and risk factors,
1–14% will have endometrial cancer [1, 2].
One concern in treating women with postmenopausal
bleeding (PMB) is whether the appropriate initial method
of evaluating is TVUS, endometrial biopsy or both.
Until the 1980s, fractional dilation and curettage (d&c)
was the procedure most often used. Although d&c is inva-
sive and is associated with a 1–2% complication rate, it
often suggests the extent of the disease and the tumor mass
[3]. However, the use of the d&c for the assessment of
endometrial pathology has serious limitations, as it has a
false-negative rate of between 2 and 6% for diagnosing
endometrial cancer and hyperplasia, while the rate of false-
positive results in the cervical fraction approaches 50%.
Diagnostic hysteroscopy with directed biopsy, if indi-
cated, is an option, particularly for patients with recurrent
bleeding despite negative curettage. It provides additional
information and accuracy by detecting early foci of cancer
that can be missed by curettage—this operation permits
taking directed biopsies, thereby minimizing the theoretical
risk of sampling errors. Hysteroscopy can also evaluate cer-
vical involvement better than fractional curettage.
Transvaginal ultrasound is a simple, non-invasive tech-
nique that can be used to discriminate between benign and
malignant endometrium, oVers a sensitive view to pelvic
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pathology and has been explored as an alternative tech-
nique to indirectly visualize the endometrium. It is used
today increasingly in the diagnostic work-up of patients
with endometrial cancer. It has high sensitivity and speci-
Wcity as a screening method in postmenopausal patients.
The odds of endometrial cancer after a negative scan (endo-
metrial thickness · 4 mm) are only one-tenth of the odds
before the scan [4, 5]. The use of hydrosonography has led
to a signiWcant increase in the diagnostic accuracy of trans-
vaginal ultrasonography. Some have suggested that color
and spectral Doppler ultrasound examination of the uterine
and subendometrial arteries can aid in the diVerentiation
between benign and malignant endometrium [6–9].
There are conXicting reports about the best way of initial
investigation of endometrial pathology and the aim of this
study is to summarize the currently available published lit-
erature on the diagnostic accuracy of pelvic ultrasonogra-
phy and endometrial biopsy for predicting endometrial
carcinoma and disease (hyperplasia and/or carcinoma).
TVUS versus histological evaluation
The accuracy of TVUS and endometrial histological biopsy
in predicting endometrial hyperplasia and endometrial car-
cinoma is a subject of continuing debate. Karlsson et al.
[10] compared the speciWcity and sensitivity of transvaginal
ultrasound and d&c to discriminate between a normal and
pathological endometrium. A speciWcity of 81% and a sen-
sitivity of 97% in diagnosing morphological alterations by
means of TVUS were found. Moreover, other authors [11]
determine the sensitivity and speciWcity for the measure-
ment of endometrial thickness using TVUS to diagnose an
endometrial abnormality at 100 and 75%, respectively. The
corresponding Wgures for hysteroscopy were 97 and 88%.
In a recent meta-analysis [12] of endometrial sampling
methods, sensitivity for detection of endometrial carcinoma
was in the range of 25–100%. The best results were from a
single study of pipelle endometrial biopsy in postmeno-
pausal women, with sensitivity of 99.6%. False-negative
rates for oYce-based endometrial biopsy have been
reported at more than 15% and d&c has up to an 11% false-
negative rate for endometrial carcinoma. One study
reported that endometrial biopsy had only a 43% sensitivity
rate for detecting endometrial carcinoma. False-positive
rates for endometrial biopsy are believed to be very low,
although no exact Wgure has been reported.
Abnormal endometrial thickness
With TVUS, it has been shown that the endometrial thick-
ness of normal atrophic uterus measures on average 2.3 mm
[13,  14]. However, advanced endometrial carcinoma has
also been known to occur in cases without noticeable endo-
metrial thickness on ultrasound [15, 16].
In a study of postmenopausal women without uterine
bleeding [3, 15], a mean endometrial thickness of 3.2 mm
was reported. Subsequently, it was reported [13] that the
mean endometrial thickness for women with PMB and a
histopathological diagnosis of atrophy was 3.4 mm. How-
ever, in the Nordic multicenter study of over 1,000 women
with PMB, the corresponding Wgure was found to be
3.9 mm (range 1–2 mm) [3, 10] (Table 1).
The data relating to endometrial thickness in the pres-
ence of carcinoma do not always demonstrate a concor-
dance. Some authors have suggested a 3-mm thickness as a
threshold, to reduce the chance of missing cases of carci-
noma at the expense of speciWcity. Auslender et al. [11]
used a cut-oV limit of 3 mm and suggested that an endome-
trial thickness of 3 mm or less as a threshold would have
reduced the number of d&c procedures by 45% and no
cases of endometrial pathologies would have been missed.
Nonetheless, in another study [16], three of nine cases of
carcinoma were found in women with an endometrial thick-
ness of 3 mm. (However, this study also reported mean
endometrial thickness lower than those in most studies, e.g.
6 mm in cases of carcinoma, suggesting that a diVerence in
technique may partially account for the Wndings.)
The earliest reports comparing TVUS with endometrial
sampling consistently found that an endometrial thickness
of less than or equal to 4–5 mm in patients with PMB reli-
ably excluded endometrial cancer. Botsis et al. [17]
reported that the mean endometrial thickness in women,
examined in their study, with endometrial cancer was
16.6 § 5.4 mm as compared with 3.2 § 1.1 mm in those
women with atrophic endometrium, and 9.5 § 2.3 mm in
those with hyperplasia and concluded that, if a cut-oV limit
of 5 mm had been used in the study, a single case of serious
endometrial pathology would not have been missed.
Subsequently, Karlsson et al. [10] in the Nordic multicenter
trial, the largest study evaluating endometrial measurements in
postmenopausal women with bleeding, found that in women
with endometrial cancer the mean endometrial thickness § SD
was 21.1 § 11.8 mm. No malignant endometrium was
Table 1 Endometrial thickness related to the histopathological diag-
nosis of atrophy in women with postmenopausal bleeding, in some
published papers
Year Mean thickness 
(mm) § SD
Range 
(mm)
Granberg et al. [13] 1991 3.4 § 1.2 2–11
Botsis et al. [17] 1992 3.2 § 1.1 –
Auslender [11] 1993 2.6 § 1.4 0–6.5
Karlsson et al. [10] 1993 3.9 § 2.5 1–22Arch Gynecol Obstet (2011) 283:261–266 263
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thinner than 5 mm. In 30 women (2.8%), it was not possible
to measure the thickness of the endometrium. The 95% conW-
dence limit for the probability of excluding endometrial
abnormality was 5.5% when the endometrial thickness was
·4 mm, as measured by TVUS. They stated that the risk of
Wnding pathologic endometrium at curettage when the endo-
metrium is ·4 mm, as measured by TVUS, is 5.5%.
Similarly, Ferrazzi et al. [18] used the same cut-oV of
4 mm with the likelihood ratio (LR) for cancer, yielded, by
an endometrial thickness of ·4.0 mm, 0.05. This cut-oV of
4.0 mm yielded a sensitivity for the detection of cancer of
98% and a negative predictive value of 99%. They have
shown that an endometrial thickness of ·4.0 mm safely
predicts endometrial atrophy and justiWes expectant man-
agement, when the patient understands the need for proper
follow-up. This could be achieved with a reduction in the
use of invasive procedures without unwanted delay in can-
cer diagnosis.
Since that time, a number of conWrmatory multicenter
trials have been completed. It has been found [19] that
endometrial cancer occurs most in women without HRT,
particularly in those women with an endometrium exceed-
ing 8 mm. Consequently, it has been demonstrated that the
cut-oV for excluding endometrial abnormalities is ·4m m .
In a subsequent study [20], an evaluation of 419 women
with PMB assessed the sensitivity of 2 endometrial thick-
ness thresholds: 4 and 8 mm. The authors reported a diag-
nostic sensitivity of 95.1% and a speciWcity of 54.8% when
using the 4-mm cut-oV, and an 83.8% sensitivity and 81.3%
speciWcity when using the 8-mm cut-oV.
A prospective diagnostic accuracy study [21] had the
following results: Using endometrial thickness · 4 mm, the
sensitivity of ultrasound to detect the endometrial malig-
nancy was 92.9%, the speciWcity was 100%, and the posi-
tive and negative predictive values were 24.1 and 97.6%,
respectively. Analysis using LR revealed that LR was 0.14
for endometrial thickness · 4.0 mm, 0.94 for endometrial
thickness 4.1–9.0 mm, and 3.3 for endometrial thickness >
9.0 mm. The study concluded that in women with PMB,
malignancy can probably be safely excluded if sonographic
endometrial thickness is ·4.0 mm.
In concordance, the study of Ciatto et al. [22] suggested
that the best cut-oV for clinical purposes is 4 mm, with a
sensitivity of 91.1%, a speciWcity of 79.8%, a positive pre-
dictive value of 14.8% and a negative predictive value of
99.6%. Moreover, in a subsequent study, Guner et al. [23]
also concluded that endometrial thickness of <4 mm may
serve as cut-oV point for predicting pathology negative
cases with an accuracy of 100% in postmenopausal women
with or without vaginal bleeding. Then, as the endometrial
thickness increases, the probability of Wnding endometrial
pathology in curettage increases linearly with a positive
predictive value of 74.6%.
Despite these encouraging results, Tsikouras et al. [24]
in a retrospective study, which included 275 patients with
PMB, reported a 8.16% prevalence of endometrial cancer
in women with PMB and endometrial thickness < 4 mm.
Using a maximum 5-mm endometrial thickness, in a study
of 182 women with PMB [25], no cases of carcinoma were
found; however, 3 patients had hyperplasia.
Another prospective study [26] tried to evaluate the opti-
mum method(s) of investigating women with PMB. The
authors concluded that an endometrial thickness of >5 mm
used as an indicator of endometrial pathology compared to
uterine curettage has a sensitivity of 83%, a speciWcity of
77%, and a positive predictive value of 54%.
Bruchim et al. [27] found that no patient had carcinoma
when the endometrium was less than 5-mm thick, but
18.5% did when the thickness exceeded 9 mm, with the
mean endometrial thickness in the presence of endometrial
carcinoma 13.5 mm (§7.7 mm) (p <0 . 0 0 5 ) .
In addition, a recent study [28] reported a 0.6% preva-
lence of endometrial cancer in women with PMB and endo-
metrial thickness < 4 mm. This prevalence increased to
19% in women with an endometrial thickness ¸ 5 mm. The
authors concluded that in women with an endometrial
thickness < 4 mm, endometrial biopsy is not required [29].
Other authors suggest that a minimum sonographically
measured endometrial thickness of 6 mm should be utilized
to reduce the number of false positives [15, 30]. Mateos
et al. [31] reported a prospective trial of TVUS evaluation
followed by endometrial sampling in 168 women with
PMB who were not receiving estrogen. They resulted in
88.6% sensitivity, 90.6% speciWcity, and 92% positive pre-
dictive value for any endometrial pathology, using a cut-oV
of 6 mm for endometrial thickness.
It is worthy of note that it has been reported [27] that
endometrial thickness and years of menopause deWne cut-oV
points for the diagnostic biopsy of tissue samples for endo-
metrial carcinoma (6 mm of endometrial thickness for
women experiencing menopause 5–15 years prior and 5 mm
in those going through menopause 15 or more years prior).
In summary, it seems that a minimum thickness of 5 mm as
the threshold for follow-up [31] biopsy would provide ade-
quate sensitivity without excessive false-positive rates in most
women and a false-negative rate of 0.25–0.50% [33, 34].
On the other hand, several studies suggest that an endo-
metrial thickness of >15 mm is highly suggestive of endo-
metrial carcinoma [35] (Tables 2, 3).
Endometrial biopsy. Is it a necessity?
Given that more than 90% of postmenopausal and more
than 98% of pre- and perimenopausal women with abnormal
bleeding will have a benign underlying cause, questions264 Arch Gynecol Obstet (2011) 283:261–266
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have arisen regarding the appropriateness of performing
biopsies on all patients with PMB. The authors, who have
studied the above speculation, have reported conXicting
results. The results of the Nordic multicenter trial [10]
showed that it would seem justiWed to refrain from curet-
tage, in women with PMB and an endometrium ·4m m .
Moreover, it has been demonstrated by other teams [33]
that if the false-negative rate of endometrial biopsy tech-
niques is taken into account, then the combination of TVUS
and cervical cytologic examination is an adequate form of
management for women with PMB as long as endometrial
thickness is ·4 mm.
Furthermore, as suggested by Ferrazzi et al. [18], trans-
vaginal sonographic measurement of endometrial thick-
ness, integrated with individual risk factors, can help in the
management of postmenopausal patients with atypical
bleeding (histological evaluation in high risk cases, or the
choice of possible expectant management).
In 2001, the Society of Radiologists in Ultrasound met to
discuss the role of sonography in women with PMB [36].
They concluded that PMB demands further evaluation and
that either transvaginal sonography or endometrial biopsy
could serve as the Wrst-line diagnostic technique, but further
studies are needed to determine which approach is more
cost-eVective.
In regard of an accurate clinical investigation, Gupta
et al. [35], in their prospective study, recommended the
combination of ultrasound and outpatient endometrial sam-
pling in all women with PMB for excluding endometrial
pathology.
In addition, the sum of the evidence from other studies
[37] suggests that TVS and hysteroscopy are complemen-
tary diagnostic methods and could be accurately used to
discriminate normal and pathologic conditions in patients
with PMB. Several authors [38] have emphasized that there
is a very good correspondence between hysteroscopy and
histology (sensitivity 97.5% and speciWcity 100%), con-
Wrming their usefulness in diagnosis of postmenopausal
uterine bleeding. Consequently, in their opinion, hysteros-
copy should be considered in all women with postmeno-
pausal uterine bleeding.
It is also important to point out that there are conXicting
reports about the case of rebleeding. Epstein et al. [6, 7]
observed that rebleeding and endometrial growth are com-
mon during a follow-up period of 12 months in women with
PMB and an endometrial thickness < 5 mm, irrespective of
whether or not d&c is primarily carried out. According to
their opinion, if these women are managed by ultrasound
follow-up, endometrial sampling should be performed if the
endometrium grows, but not necessarily in the case of reb-
leeding without endometrial growth. This view point is very
well supported by the study of Van Doorn et al. [39].
According to the results of their study, 8% of the women
with recurrent bleeding turned out to have an endometrial
carcinoma. These women had presented with a Wrst episode
of PMB, an endometrial thickness · 4 mm at TVUS and
median time until recurrence of bleeding was 49 weeks.
Table 2 Endometrial thickness 
and cancer Wndings in postmen-
opausal women with bleeding
Reference Endometrial 
thickness (mm)
Number of
women
Number of cases
of cancer
Negative predictive 
value (%)
Karlsson et al. [10] ·4 1,168 0 100
Ferrazzi et al. [18] ·4 930 2 99.8
·5 4 99.6
Gull et al. [28] ·4 163 1 99.4
Epstein et al. [32] ·5 97 0 100
Gull et al. [29] ·4 394 0 100
Bruchim et al. [27] ·5 95 0 100
Epstein and Valentin [6] ·4.5 95 12 87.4
Tsikouras et al. [24] ·4 275 4 98.5
Table 3 The risk of endometrial cancer at various endometrial thick-
ness measurements in women who are symptomatic or asymptomatic
with vaginal bleeding
Threshold to deWne 
a normal endometrium 
(mm)
Women with vaginal bleeding: cancer 
risk (%) if the endometrium
·Threshold >Threshold
·40 . 0 7 4 . 6
·50 . 0 7 7 . 3
·60 . 0 8 7 . 7
·70 . 0 9 1 0 . 8
·80 . 1 2 1 2 . 7
·90 . 1 4 1 5 . 1
·10 0.18 16.6
·11 0.21 40.3
·12 0.25 42.1
·13 0.30 48.2
·14 0.36 52.2
·15 0.42 53.5Arch Gynecol Obstet (2011) 283:261–266 265
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Conclusions
In summary, similar sensitivities for detecting endometrial
carcinoma are reported for transvaginal sonography when
an endometrial thickness of greater than 5 mm is consid-
ered abnormal and for endometrial biopsy when “suY-
cient” tissue is obtained. Despite the above outcome,
controversy remains regarding the relative roles of these
uterine imaging modalities. Future research needs to be
directed toward providing eVectiveness and cost-eVective-
ness. So, as the exclusion of endometrial cancer is very
important and due to respect to woman’s health and qual-
ity-of-life end points, there is an urgent need in the future
for better quality primary accuracy studies using ideal ref-
erence standards and good-quality criteria to guide decision
making.
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